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Background: The role of the tumor necrosis factor receptor associated protein 1 (TRAP1) – supposed to be
involved in protection of cells from apoptosis and oxidative stress – has just started to be investigated in ovarian
cancer. TRAP1 has been shown to be estrogen up-regulated in estrogen receptor α (ERα) positive ovarian cancer
cells. The clinical impact of TRAP1 is not clear so far and the significance of ERα expression as therapeutic and
prognostic marker is still controversial. Therefore, we investigated the importance of TRAP1 together with ERα in
regard to clinicopathological parameters, chemotherapy response, and survival.
Methods and results: Expressions of TRAP1 and ERα were evaluated by immunohistochemical staining of tissue
microarrays comprised of 208 ovarian cancer samples. TRAP1 was highly expressed in 55% and ERα was expressed
in 52% of all cases. High TRAP1 expression correlated significantly with ERα (p < 0.001) but high TRAP1 expression
was also found in 42% of ERα negative cases. High TRAP1 expression correlated significantly with favorable
chemotherapy-response (HR = 0.48; 95%CI 0.24-0.96, p=0.037) and showed a significant impact on overall survival
(OS) (HR = 0.65; 95%CI 0.43-0.99, p = 0.044). ERα expression was a favorable prognostic factor for OS in univariate
and multivariate analyses. Interestingly, the combined pattern (ERα positive and/or TRAP1-high) revealed the
strongest independent and significant positive influence on OS (HR = 0.41; 95%CI 0.27-0.64).
Conclusion: Immunohistochemical evaluation of TRAP1 together with ERα provides significant prognostic
information. TRAP1 alone is significantly associated with chemotherapy response and overall survival, rendering
TRAP1 as interesting scientific and therapeutic target.
Keywords: TRAP1, Estrogen receptor, Immunohistochemistry, Prognosis, Ovarian cancerIntroduction
Molecular chaperones of the Hsp90 (90-kDa heat shock
protein) family are involved in cancer development and
malignant progression. TRAP1/Hsp75 (tumor necrosis
factor receptor associated protein 1), a paralogue of the
Hsp90 family, has been recently described as a molecular
marker and novel therapeutic target in local and meta-
static prostate cancer [1]. Increased expression of
TRAP1 in multidrug resistant colorectal cancer was* Correspondence: dietmar.pils@univie.ac.at
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reproduction in any medium, provided the orsuggested to favor chemotherapy resistance [2]. In breast
cancer cells, HSPs influence tumorigenesis [3] and in
ovarian cancer, TRAP1 has recently been questioned as
a new potential molecular target [4].
Ovarian cancer is the leading cause of death from
gynecologic malignancies in western countries, whereby
peritoneal metastasis and chemotherapy resistance as
well as relapse after chemotherapy remain scientific and
clinical challenges. Trying to understand the mechan-
isms involved in cancer progression and chemotherapy
resistance in epithelial ovarian carcinoma (EOC), the
role of heat shock proteins, including TRAP1, has just
started to be investigated [4-6].d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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amount on the ability of ovarian cancer cells to undergo
drug-induced apoptosis [7]. TRAP1, described to be
involved in apoptosis evasion, was observed to be sig-
nificantly up-regulated in Cisplatin resistant ovarian
tumor cell lines [8]. Microarray analysis of expression
changes in human ERα-positive ovarian cancer cell lines
upon 17ß-estradiol stimulation, identified TRAP1 to be
estrogen up-regulated and to be involved in growth
regulation of EOC [9]. In certain EOCs, high levels of
ERα are frequently expressed at time of diagnosis and
expression levels of ERα dependent up-regulated pro-
teins such as TRAP1 were discussed to predict endo-
crine responsiveness [10].
However, the importance of ERα expression as thera-
peutic and prognostic marker in EOC is still controver-
sial [11]. Prognostic significance of ERα expression was
recently described as favorable, revealing a significantly
longer overall survival [12-14]. However, in other studies
this was not observed [15,16]. In young women, the ex-
pression of ER alone was not associated with favorable
survival but the combination of ER+/PR + revealed a su-
perior overall survival [17]. Additionally, superior prog-
nosis was described in ER-/PR + invasive ovarian cancer
[18] when compared to all other combinations. Thus,
TRAP1 might become of relevance when predictors of
endocrine therapy response in EOC will be further
elucidated.
Up to now, only a limited number of studies have fo-
cused on this Hsp90 related molecule and most of the
results were obtained from cell line models or mouse
models [19,20]. TRAP1’s levels are consistently elevated
in several human malignancies (i.e. colon, prostate, and
nasopharyngeal carcinomas), while present at very low
levels, and sometimes undetectable in the corresponding
normal tissues. In EOC, a number of studies have inves-
tigated the association of differences in gene expression
at time of primary surgery and therapy-response [21,22].
It has been demonstrated that estrogen-regulated gene
expression can predict response to endocrine therapy
with the aromatase inhibitor Letrozole in patients with
ovarian cancer. The expression of estrogen-regulated
genes such as TRAP1, TFF1, TFF3, TOP2A and UBE2C
was significantly different between CA125 progressors
and non-progressors in a sample of 42 patients after
treatment with Letrozole, whereby TRAP1 was signifi-
cantly increased in Letrozole-responsive patients [10].
The aim of our study was to further clarify the role of
TRAP1 in a large and homogenous sample of human
EOC in regard to clinicopathological parameters, ther-
apy response, and patient outcome. We examined the
pattern of TRAP1 expression in prospectively collected
ovarian tumor tissue from 208 non-FIGO I patients col-
lected in the course of the EU-project OVCAD (OvarianCancer: Diagnosis of a silent killer, no. 018698). To bet-
ter understand the function of TRAP1 and to provide
further insight into the relationship between ERα expres-
sion and tumor behavior as well as patients’ outcome,
expression levels of ERα were analyzed as well and cor-
related with clinicopathological parameters.
Materials and methods
Patients cohort
Within the context of the FP6 EU-project OVCAD
(http://www.ovcad.org), samples from primary EOC
were prospectively collected at the University clinics of
Berlin, Hamburg, Innsbruck, Leuven, and Vienna
(OVCAD-consortium). Samples were collected accord-
ing to standard operation procedures established in
OVCAD. Clinical and histopathological data as well as
follow-up data were collected by experienced clinicians.
Patients presenting with benign ovarian diseases, FIGO I
stage EOC or secondary malignant diseases were
excluded. 85% of Patients were treated according to
standards of the institutions involved with upfront sur-
gery and adjuvant platinum–based chemotherapy. A
total of 31 patients (14.9%) were treated with neoadju-
vant chemotherapy (platinum–based) followed by an
intervention-debulking and further adjuvant chemother-
apy. Only patients with debulking surgery and plat-
inum–based chemotherapy were included to the
OVCAD patient cohort. The study protocol was
approved by the Ethics Committees of the participating
OVCAD partners. All patients gave pre-operative writ-
ten informed consent before enrollment in the study.
Overall survival (OS) was defined as the time interval
between diagnosis and cancer correlated death and pro-
gression free survival (PFS) as the time between diagno-
sis and disease progression. Overall observation time
was the time interval between diagnosis and last contact,
defined as death or last follow-up. Therapy response to
chemotherapy was defined according to the WHO cri-
teria; i.e. progression of disease after first-line chemo-
therapy was defined by an increase in the nadir serum
CA-125 level of at least two according to the GCIG cri-
teria or by radiological confirmation. Patients were clas-
sified as non-responder if progression was diagnosed
during treatment or recurrence within six months after
end of first-line chemotherapy. Patients without recur-
rence, cancer progression or death were censored at the
time of last follow-up. Experienced gynecological oncol-
ogists and pathologists performed the clinical and histo-
pathological evaluation and the evaluation of response
to first-line treatment.
Immunostaining
Five tissue microarrays (TMAs) comprised of two tissue
sections of 208 patients per patient were analyzed.
Table 1 Characteristics of the study population
Study population divided into TRAP1-low and TRAP1-high
N=208 TRAP1-low TRAP1-high






≤ 55 (n = 98) 49 (23.6) 49 (23.6)
> 55 (n = 110) 44 (21.2) 66 (31.7) 0.148
Histology
Serous (n = 183) 76 (36.5) 107 (51.4)
Non-serous1 (n = 25) 17 (8.2) 8 (3.8) 0.013 0.078
FIGO
II (n = 9) 5 (2.4) 4 (1.9)
III (n = 164) 70 (33.6) 94 (45.2) 0.5262
IV (n = 35) 18 (8.7) 17 (8.2)
Grade (1missing)
Grade 1&2 (n = 55) 19 (9.2) 36 (17.4)
Grade 3 (n = 152) 73 (35.3) 79 (38.2) 0.087
Residual tumor
no (n = 146) 64 (30.8) 82 (39.4)
> 0 cm (n = 62) 29 (13.9) 33 (15.9) 0.697
Peritoneal Carcinomatosis
no (n = 64) 28 (13.5) 36 (17.3)
yes (n = 144) 65 (31.5) 79 (38.0) 0.852
1Endometrioid (n = 9), mixed epithelial (n = 9), mucinous (n = 1), undifferentiated
(n = 4), and clear-cell carcinoma (n = 2). 2Fisher’s Exact test.
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chondrial staining of monoclonal rabbit anti-TRAP1
antibody (1:1,000; Cat-Id/Clone-ID 3609-1/EPR5381,
Epitomics, USA) was verified by a colocalization analysis
employing double-immunofluorescence staining with
mouse anti-COX5 antibody as mitochondrial marker
(1:250; Invitrogen). The fluorescence labeled secondary
antibodies, goat anti-rabbit (1:5,000; Invitrogen, Alexa-
FluorW 488 fragment of goat anti-rabbit IgG (H+L)) and
goat anti-mouse (1:5,000; Invitrogen, AlexaFluorW 568
goat anti-mouse IgG1) were used besides DAPI for nu-
clear counterstaining. For the TMA, two replicate
1 mm-diameter cores were obtained. Three μm sections
were deparaffinized, rehydrated, and quenched for en-
dogenous peroxidase by incubating with 3%H2O2. For
TRAP1 staining (1:3,000; Epitomics) epitope heat re-
trieval was performed by microwaving the slides in
EDTA (0.01 M, pH 8.0). Samples were blocked with
blocking solution (Ultra V Block; TA-015HP) for 7 min
and then the primary TRAP1 antibody was added for
one hour at room temperature. As a positive control,
kidney tissue sections were used and for negative con-
trol, a rabbit immunoglobulin control. For enhancement,
slides were incubated with primary antibody enhancer
(Primary Antibody Enhancer; TL-015-PB) for 10 min
followed by a HRP Polymer (HRP Polymer; TL-015-PH)
for 15 min. Finally, slides were incubated with diaminoben-
zidin as a chromogen, counterstained with hematoxylin,
dehydrated and mounted.
TRAP1 expression levels were determined using a
scoring system based on the intensity of staining (0–3)
compared to the negative control (0). Samples were
examined by three independent observers, including a
gynecological pathologist, whereby rescoring was con-
ducted in samples with inconsistent scoring, leading to
the following groups: negative (0); weak (1); moderate
(2); and strong (3) staining. For statistical analysis classi-
fication into TRAP1-high and TRAP1-low was per-
formed according to strong versus negative to moderate
expression levels, respectively.
Staining for ERα (1:50; ERα, clone 1D5, mouse IgG1,
Dako, Denmark) was performed using standard immu-
nohistochemical techniques. The intensity patterns and
nuclear positivity of ERα staining were analyzed by
two independent co-workers, including a gynecological
pathologist, applying a semi-quantitative scale of Immu-
noReactive Score (IRS) including intensity of color reac-
tion and percentage of positive cells. The intensity of
reaction was scored as negative (intensity 0, <10% posi-
tive cells) or positive (intensity 1–3, >10% positive cells).
Statistical analysis
Statistical analyses were performed using SPSS software
version 19 (IBM Corporation, Armonk, New York,USA). Correlations between TRAP1-expression, ERα-ex-
pression, and clinicopathological parameters were
assessed by T-tests, Chi-square tests, and Fisher’s exact
tests as appropriate. Results were adjusted for multiple
testing by the Bonferroni-Holm method [23]. To analyze
ERα together with TRAP1 expression, patients were
classified into four groups: i) ERα-/TRAP1-low; ii) ERα-/
TRAP1-high; iii) ERα+/TRAP1-low; iv) ER+/TRAP1-
high; For survival analyses and impact on chemotherapy
response, the following combination pattern was
included in the calculations: i) a group comprised of
ERα-/TRAP1-low versus ii) a group comprised of the
other three combinations. Impact on progression free
survival and overall survival was determined by univari-
ate and multiple Cox proportional-Hazards model ana-
lyses. Impact on chemotherapy response was determined
by uni- and multivariate logistic regression models. In
addition, the univariate impact was illustrated by
Kaplan-Meier estimates whereby differences in survival
were analyzed by the Log-rank test.
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Study population
Tumor tissues of 208 EOC patients were used. Median
age at time of cytoreductive surgery was 56 years (range
18–85 years). All 9 (4%) patients with FIGO II EOC
received optimal cytoreductive surgery as well as 137
(66%) of the 199 patients diagnosed with FIGO III and
IV. Within the observation period 96 patients died and
the median follow up was 51 months. The clinicopatho-
logical characteristics of the 208 EOCs classified as
TRAP1-high or TRAP1-low are shown in Table 1.
No significant differences were found for the clinico-
pathological parameters between the two groups
(adjusted p-values).
Immunohistochemical evaluation
Initially, expression of the molecular chaperone TRAP1
in human ovarian cancer was determined by immuno-
histochemistry. 115 patients were classified as TRAP1-
high (55.3%) and 93 patients as TRAP1- low (44.%),
comprising moderate, low, and negative expression in 57
(27.4%), 25 (12.0%), and 11 (5.3%) samples, respectively.
To proof the mitochondrial expression of the used anti-
body, a colocalization experiment was conducted, using
the mitochondrial marker COX5 together with TRAP1.
In Figure 1, an example of this double-staining is given,Figure 1 Colocalization analysis of TRAP1 (green) and the mitochond
staining in an EOC sample. The images show that both TRAP1 and COX5
confocal microscope LSM700).showing the mitochondrial localization of TRAP1 in an
EOC tissue. On the TMA, tumor tissue showed a dis-
tinct specific intracytoplasmatic granular staining,
reflecting the expected mitochondrial localization. To
confirm the antibody specificity, a Western blot and
staining of paraffin embedded agarose cell blocks of four
cell lines (two with high, one with weak, and one with
nearly no TRAP1 expression) have been conducted. The
Western blot showed a perfect specificity (no additional
bands besides the correct band at Mr ~ 75,000) of the
TRAP1 antibody. A near perfect correlation of the West-
ern band intensities to the staining intensities of the cor-
responding stainings of the agarose cell blocks was
observed (supplementary data in additional file 1). Sam-
ples of studied ovarian cancer tissues with variable
staining intensities are presented in Figure 2A. Tumor-
surrounding stromal tissue showed no TRAP1 expres-
sion (Figure 2A).
The results of ERα immunohistochemistry analysis
revealed 99 (48%) ERα negative and 109 (52%) ERα
positive cases. Representative pictures of ERα staining
are provided in Figure 2B. Table 2 describes the charac-
teristics of ERα positive and negative patients. There was
a significant correlation between ERα expression and the
histological classification: tumors of non-serousrial marker COX5 (red) using double-immunofluorescence
are localized in the mitochondria. (Pictures were taken with the
Figure 2 A) Representative immunohistochemical staining of TRAP1 in four different EOC samples classified as TRAP1 negative (0);
weak (1); moderate (2); and strong (3); surrounding stromal tissue showed no TRAP1 staining; B) Staining of ERα (a, c) highly positive
(strong intensity of nuclear staining, >80% positive nuclei), (b) <10% of nuclei show weak staining, and (d) completely negative for
nuclear ERα staining, were scored as ERα negative. Pictures were taken using TissueFAXS (TissueGnostics; Vienna, Austria).
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p = 0.045).
To determine the relationship between ERα expression
and TRAP1 expression, the Chi-square test was used.
Ovarian cancer tissues expressing ERα were more likely
to show high TRAP1 expression levels (67.0%, p < 0.001).
Correspondingly, low TRAP1 expression levels were
found in the majority of ERα negative tissues. Still, 42.2%
of ERα negative samples presented high TRAP1 levels.
Relevance of ERα and TRAP1 expression for
chemotherapy response and patients’ survival
In Table 3A,B the impact of TRAP1, ERα, and the com-
bined TRAP1/ERα expression pattern on OS and PFS,
together with various clinicopathological parameters
considered as potential prognostic factors, is presented.
Univariate analyses identified age (in decades) (HR=
1.44; 95%CI [1.21-1.71]), FIGO stage (HR 1.96; 95%CI[1.25-3.06]), grade (HR 1.74; 95%CI [1.05-2.88]), residual
tumor load (HR =2.35; 95%CI [1.54-3.61]), peritoneal
carcinomatosis (HR= 3.01; 95%CI [1.75-5.16]), ERα
(HR= 0.56; 95%CI [0.37-0.84]), TRAP1 (HR 0.63; 95%CI
[0.42-0.94]), and the combination pattern ERα/TRAP1
(HR=0.49; 95%CI [0.32-0.75]) to be significantly asso-
ciated with OS. For PFS, the parameters age, FIGO-stage,
grade, residual tumor load, and peritoneal carcinomatosis
showed significant impact (Table 3B).
In a next step, multivariate Cox proportional-hazards
regression analyses of patients’ OS and PFS, based on
clinicopathological factors together with either i) TRAP1
expression, ii) ERα expression or iii) the combination
pattern, was performed. Multivariate analyses identified
ERα and TRAP1 to have an independent impact on OS
(HR= 0.51; 95%CI [0.34-0.77] and HR= 0.65; 95%CI
[0.43-0.99]), respectively). The TRAP1/ERα-combination
pattern was an even stronger significant independent
Table 2 Study population divided into ERα negative (ERα-)
and ERα positive (ERα+)
N=208 ERα- ERα+
Characteristics n = 99 (%) n = 109 (%) p Adjusted p
Age
≤ 55 (n = 98) 55 (26.4) 43 (20.7)
> 55 (n = 110) 44 (21.2) 66 (31.7) 0.026 0.080
Histology
Serous (n = 183) 81 (38.9) 102 (49.0)
Non-serous1 (n = 25) 18 (8.7) 7 (3.4) 0.009 0.045
FIGO2
II (n = 9) 3 (1.4) 6 (2.9)
III (n = 164) 76 (33.6) 88 (42.3) 0.1582
IV (n = 35) 20 (9.6) 15 (7.2)
Grade (1 missing)
Grade 1&2 (n = 55) 18 (8.7) 37 (17.9)
Grade 3 (n = 152) 81 (39.1) 71 (34.3) 0.009 0.054
Residual tumor
no (n = 146) 66 (31.7) 80 (38.5)
> 0 cm (n = 62) 33 (15.9) 29 (13.9) 0.289
Peritoneal Carcinomatosis
no (n = 64) 31 (14.9) 33 (15.9)
yes (n = 144) 68 (32.7) 76 (36.5) 0.871
1Endometrioid (n = 9), mixed epithelial (n = 9), mucinous (n = 1), undifferentiated
(n = 4), and clear-cell carcinoma (n = 2). 2Fisher’s Exact test.
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(Table 3A). Age and peritoneal carcinomatosis showed a
comparably strong influence on OS. FIGO stage, residual
tumor load and peritoneal carcinomatosis had a signifi-
cant impact on PFS.
In Table 3C the impact of TRAP1, ERα, and the com-
bined TRAP1/ERα expression pattern on the response
to first-line chemotherapy is shown. The risk to be a
non-responder was significantly lower in patients with
high TRAP1 expression compared to patients with low
TRAP1 expression, both, in a univariate (HR= 0.53; 95%
CI [0.28-1.00]) and a multivariate analysis (HR= 0.48;
95%CI [0.24-0.96]). A similar but not significant impact
was found for ERα positivity in a univariate (HR= 0.62;
95%CI [0.33-1.17]) and a multivariate analysis (HR=
0.53; 95%CI [0.26-1.05]). Combining both factors, halves
the observed risk to be a non-responder compared to
the risk of patients with TRAP1 high or ERα positive
tumors, in the univariate (HR= 0.38; 95%CI [0.19-0.75])
and multivariate (HR= 0.24; 95%CI [0.11-0.54]) analysis,
indicating an additive effect of both markers.
Figure 3 shows the univariate impact of ERα, TRAP1,
and the combination pattern on PFS and OS as esti-
mated by Kaplan Meier plots. Stratifying the patients
into two groups according to their combined TRAP1/ERα expression level yields the strongest predictive fac-
tor, which was also seen from the corresponding mul-
tiple Cox proportional-hazards regression models (data
not shown). Patients presenting with a double negative
expression pattern (TRAP1-low/ERα-) at time of cytore-
ductive surgery appear to have a considerably decreased OS
(p<0.001) and PFS (p=0.005) compared to patients with
positive expression levels of both or one of the examined
parameters (Figure 3). Further stratification of group 2 into
TRAP1high/ERα- (group 2a) and TRAP1low/ERα+ (group
2b), and TRAP1high/ERα+ (group 2c) did not improve
this predictive capacity, as shown for OS in Figure 4 (dif-
ferences not significant).Discussion
We have evaluated the expression of ERα in EOC to-
gether with the expression of TRAP1, that has been
described to be up-regulated in vitro in ER positive ovar-
ian cancer cells exposed to estrogen [9]. To our know-
ledge, this is the first study evaluating the impact of
TRAP1 expression on patients’ outcome in a large pro-
spectively collected cohort of more than 200 patients
with EOC and the first study evaluating the combined
prognostic impact of TRAP1 and ERα.
Correlation of ERα with TRAP1 was significant,
whereby ERα positive tumors presented significantly
higher expression levels of TRAP1. However, high
TRAP1 levels were also found in 42% of ER negative
tumors, revealing two independent but interconnected
parameters i) ERα, described to play a dominant role in
ovarian cancer [24,25] and ii) TRAP1, a mitochondrial
chaperone, selectively up-regulated in tumor cells [19]
and up-regulated by estrogen [10].
ERα expression was not significantly associated with
stage and grade, which is in accordance with the study
of Hecht et al. [26]. Additionally, we found no signifi-
cant correlation with age, peritoneal carcinomatosis, and
residual tumor load. Tumors with non-serous histology
were more likely to be ERα negative (adj. p = 0.045) com-
pared to serous histology, which is in accordance with
the findings of Lee et al. [15]. Studies on ERα expression
and survival are inconsistent [12-16,18,27]. The results
of this study show a significantly longer OS for ERα
positive patients in a multiple Cox regression analysis.
TRAP1 expression showed a significant and independent
impact on chemotherapy responder status and on
patients’ OS. Combining TRAP1 and ERα expression,
patients with ERα negative and TRAP1-low expressing
tumors, compared to all other combinations, showed a
2.44-fold higher risk to die. This indicates a subcohort of
EOC patients presenting with a low TRAP1 expression
and a negative estrogen receptor status exhibiting a
worse prognosis.
Table 3 Multiple Cox and logistic regression analyses for (A) overall survival, (B) progression free survival, and
(C) chemotherapy response of clinicopathological parameters, ERα, TRAP1, and the ERα/TRAP1 expression pattern
A) Overall survival
N= 208 Univariate Multivariate
ERα TRAP1 Combination
Characteristics HR (CI95%) p HR (CI95%) p HR (CI95%) p HR (CI 95%) p
Age (per decade) 1.44 (1.21-1.71) <0.001 1.40 (1.17-1.68) <0.001 1.42 (1.18-1.71) <0.001 1.50 (1.24-1.82) <0.001
Histology (non-serous vs serous) 1.05 (0.57-1.92) 0.874 1.20 (0.64-2.27) 0.555 1.22 0.65-2.29) 0.545 1.33 (0.70-2.52) 0.381
FIGO (IV vs III vs II) 1.96 (1.25-3.06) 0.003 1.39 (0.85-2.25) 0.187 1.38 (0.85-2.24) 0.188 1.39 (0.86-2.27) 0.176
Grade (3 vs 1,2) 1.74 (1.05-2.88) 0.032 0.98 (0.58-1.67) 0.951 1.34 (0.67-1.92) 0.631 0.96 (0.57-1.64) 0.893
Residual tumor (yes vs no) 2.35 (1.54-3.61) <0.001 1.87 (1.21-2.89) 0.005 1.79 (1.16-2.77) 0.009 1.80 (1.17-2.78) 0.008
Peritoneal Carcinomatosis (yes vs no) 3.01 (1.75-5.16) <0.001 2.75 (1.56-4.84) <0.001 2.45 (1.38-4.32) 0.002 2.68 (1.51-4.74) 0.001
ERα (1/2/3 vs 0) 0.56 (0.37-0.84) 0.005 0.51 (0.34-0.77) 0.002
TRAP1 (3 vs 0/1/2) 0.63 (0.42-0.94) 0.025 0.65 (0.43-0.99) 0.044
Combination ERα/TRAP1* 0.49 (0.32-0.75) 0.001 0.41 (0.27-0.64) <0.001
B) Progression free survival
Characteristics HR (CI95%) p HR (CI95%) p HR (CI95%) p HR (CI 95%) p
Age (per decade) 1.21 (1.06-1.38) 0.041 1.14 (0.99-1.31) 0.056 1.15 (1.00-1.32) 0.055 1.17 (1.02-1.35) 0.027
Histology (non-serous vs serous) 0.91 (0.55-1.49) 0.701 1.23 (0.72-2.11) 0.453 1.25 (0.73-2.15) 0.416 1.25 (0.72-2.14) 0.428
FIGO (IV vs III vs II) 2.48 (1.69-3.62) <0.001 1.85 (1.22-2.79) 0.004 1.91 (1.26-2.89) 0.002 1.91 (1.26-2.89) 0.002
Grade (3 vs 1,2) 1.49 (1.03-2.17) 0.035 0.93 (0.62-1.39) 0.721 0.95 (0.64-1.41) 0.794 0.89 (0.59-1.33) 0.559
Residual tumor yes vs no) 1.99 (1.45-2.75) <0.001 1.56 (1.11-2.18) 0.010 1.55 (1.10-2.17) 0.011 1.56 (1.11-2.18) 0.010
Peritoneal Carcinomatosis (yes vs no) 2.96 (2.01-4.37) <0.001 2.98 (1.95-4.55) <0.001 2.92 (1.91-4.47) <0.001 3.00 (1.96-4.60) <0.001
ERα (1/2/3 vs 0) 0.84 (0.62-1.15) 0.279 0.80 (0.58-1.11) 0.185
TRAP1 (3 vs 0/1/2) 0.87 (0.63-1.18) 0.367 0.87 (0.63-1.20) 0.398
Combination ERα/TRAP1* 0.79 (0.56-1.12) 0.188 0.70 (0.48-1.02) 0.061
C) Chemotherapy response
Characteristics HR (CI95%) p HR (CI95%) p HR (CI95%) p HR (CI 95%) p
Age (per decade) 1.33 (1.02-1.74) 0.036 1.42 (1.06-1.9) 0.019 1.43 (1.06-1.91) 0.019 1.57 (1.15-2.15) 0.005
Histology (non-serous vs serous) 0.74 (0.26-2.08) 0.567 0.92 (0.30-2.83) 0.889 0.93 (0.30-2.83) 0.893 0.88 (0.28-2.73) 0.824
FIGO (IV vs III vs II) 2.06 (1.02-4.15) 0.044 1.59 (0.73-3.49) 0.241 1.65 (0.76-3.61) 0.207 1.67 (0.75-3.72) 0.205
Grade (3 vs 1,2) 1.17 (0.56-2.44) 0.683 0.72 (0.32-1.64) 0.437 0.76 (0.33-1.72) 0.505 0.56 (0.23-1.33) 0.188
Residual tumor (yes vs no) 1.96 (1.01-3.80) 0.046 1.35 (0.67-2.75) 0.411 1.43 (0.71-2.91) 0.318 1.36 (0.66-2.81) 0.408
Peritoneal Carcinomatosis (yes vs no) 3.01 (1.32-6.85) 0.009 3.04 (1.25-7.36) 0.014 2.89 (1.19-7.01) 0.018 3.34 (1.34-8.36) 0.009
ERα (1/2/3 vs 0) 0.62 (0.33-1.17) 0.138 0.53 (0.26-1.06) 0.071
TRAP1 (3 vs 0/1/2) 0.53 (0.28-1.00) 0.050 0.48 (0.24-0.96) 0.037
Combination ERα/TRAP1* 0.38 (0.19-0.75) 0.005 0.24 (0.11-0.54) < 0.001
*ERα and/or TRAP1 high vs ERα- and TRAP1 low.
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http://www.molecular-cancer.com/content/11/1/69Up to now, only one study has addressed TRAP1 pro-
tein expression in human ovarian cancer tissue in regard
to therapy response. Walker et al. have described signifi-
cantly increased expression levels of TRAP1 in
Letrozole-sensitive tumors if compared to resistant
tumors, suggesting that endocrine responsiveness might
be predictable with the help of estrogen regulated genes
and their expression levels [10]. Still, the association of
TRAP1 expression in patients receiving Letrozole ther-
apy and response has not been investigated in amultivariate model, and thus, the independent impact of
TRAP1 on response to therapy remains unclear. There-
fore, we focused on the predictive independent impact
of TRAP1 and ERα on response to standardized chemo-
therapy and on patients’ outcome. In accordance with
the study of Walker et al. [10], our results show that
high TRAP1 expression is positively associated with
therapy-response. Patients with high TRAP1 expression
have a two-fold higher response-rate to first-line chemo-





















































































TRAP1 low / ER -
TRAP1 high or ER +
TRAP1 low / ER -
TRAP1 high or ER +
p = 0.357
p = 0.269
p = 0.178 p < 0.001
p = 0.004
p = 0.023
Figure 3 Kaplan-Meier estimates of the impact of TRAP1, ERα, and the combination pattern on PFS and OS (p values determined by
the log-rank test).
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http://www.molecular-cancer.com/content/11/1/69show a two-fold higher response rate, but only as trend
when corrected for clinicopathological parameters. For
the combined expression pattern of TRAP1 and ERα, a
more than four-fold higher risk to be a chemotherapy
non-responder for patients with TRAP1 weak and ERα
negative tissues could be observed (p < 0.001). Most ofthe current knowledge on TRAP1 has been derived by
cell-line models and mouse-models [28,29]. This is the
first study investigating TRAP1 in the complex biology
of EOC patients treated with standardized chemother-
apy. In cell line models investigating Cisplatin resistance
only weak differences in the TRAP1 expression (1.1-1.2
Figure 4 Kaplan-Meier estimates comparing the impact of all
four groups of the combined TRAP1-ERα pattern on OS. Black
line: ERα negative/TRAP1-low; dotted black line: ERα negative/
TRAP1-high; grey line: ERα positive/TRAP1-high; dotted grey line:
ERα positive/TRAP1-low.
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http://www.molecular-cancer.com/content/11/1/69fold) between resistant and sensitive cells were observed
[8]. The authors therefore concluded that TRAP1 might
not lead to resistance in an in vitro model.
As shown with small interfering RNA gene-silencing
of TRAP1 in a lung cancer cell line and re-expression in
a breast cancer cell line, TRAP1 expression seems not to
be associated with apoptosis [30]. This is in conflict
with a variety of studies, proposing anti-apoptotic
and anti-oxidative functions of TRAP1 [19,20,29].
As shown above for human EOC patients, high TRAP1
expression – as determined by immunohistochemistry –
reveals significantly better response to chemotherapy
and a longer OS. To better understand the conflicting
data within different in vitro models and between some
in vitro models and our in vivo survival analyses, the role
of TRAP1 in EOC needs to be further elucidated.
Conclusion
As only few studies are available on the role of TRAP1
in EOC, this study enhances the knowledge upon the
crosstalk between TRAP1 and ERα in clinical samples.
However, caution is needed in the biological interpret-
ation of TRAP1’s role in human EOC. Indeed, several
reports suggested that TRAP1 is involved in protection
from apoptosis. Thus, the finding that EOC patients
with high TRAP1 expression are characterized by an ad-
vantage in chemotherapy response and overall survival
would suggest a converse involvement of TRAP1 in anin vivo setting, e. g. that TRAP1 is a (surrogate) marker
for stressed, thus apoptosis prone, tumor cells. This
would explain the positive impact of high TRAP1 ex-
pression on chemotherapy response and overall survival.
In such a perspective, further studies in either EOC cell
lines or human EOC series are needed to understand the
biological and clinical role of HSP90 chaperones in ovar-
ian carcinogenesis.
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